When a patient hits the maximum GLP-1 dose, it can feel like the end of the road — but clinicians say it's really the start of a new phase. Experts recommend reframing this milestone as "active maintenance," shifting nutrition counseling from calorie restriction to calorie quality (think lean protein, fiber, vegetables, and hydration), and adding regular resistance training to preserve lean muscle mass. Patients should also be coached to watch for early warning signs of regain — like the return of "food noise" or increased cravings — not just changes on the scale.

When GLP-1s alone aren't enough, the toolkit expands. Clinicians can consider tapering, dose spacing, switching medications, or adding a second or third obesity drug — mirroring how chronic conditions like hypertension or diabetes are managed with combination therapy. For patients who still haven't reached a healthy weight range, minimally invasive bariatric surgery (like laparoscopic sleeve gastrectomy) is another viable path, and some surgeons are now combining it with GLP-1s for an additive effect.

Key Takeaways:

• Treat max-dose GLP-1 therapy as a maintenance phase, not a treatment endpoint
• Prioritize resistance training and adequate protein to protect lean mass during weight loss
• Monitor weight, appetite, cravings, body composition, and labs (e.g., A1c) proactively
• Consider combination pharmacotherapy or bariatric surgery when single-agent GLP-1 therapy falls short

Why it matters: With GLP-1 discontinuation rates high and weight regain common, having a clear clinical plan at the maximum dose — before problems arise — is essential to sustaining long-term outcomes for patients with obesity.